Rheumatology, Osteoarthritis, Extracellular Matrix Research
7. Apr 2020
Sprifermin (rhFGF18) Versus Vehicle Induces a Biphasic Process of Extracellular Matrix Remodeling in Human Knee OA Articular Cartilage Ex Vivo
Sprifermin, recombinant human fibroblast growth factor 18 (rhFGF18), induces cartilage regeneration in knees of patients with osteoarthritis (OA). We hypothesized that a temporal multiphasic process of extracellular matrix (ECM) degradation and formation underlie this effect. We aimed to characteriz…
Read the publication
Journal:
Authors:
- Reker D,
- Siebuhr AS,
- Thudium CS,
- Gantzel T,
- Ladel C,
- Michaelis M,
- Aspberg A,
- Berchtold MW,
- Karsdal MA,
- Gigout A,
- Bay-Jensen AC,
Rheumatology, Osteoarthritis, Extracellular Matrix Research
14. Nov 2019
Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors.
OBJECTIVE:
Links between pain and joint degradation are poorly understood. We investigated the role of activation of Toll-like receptors (TLR) by cartilage metabolites in initiating and maintaining the inflammatory loop in OA causing joint destruction.
METHODS:
Synovial membrane explants (SMEs)…
Read the publication
Journal:
Authors:
- Sharma N,
- drobinski P,
- Kayed A,
- Chen Z,
- Kjelgaard-Petersen CF,
- Gantzel T,
- Karsdal MA,
- Michaels M,
- Ladel C,
- Bay-Jensen AC,
- Lindemann S,
- Thudium CS,
Rheumatology, Osteoarthritis
26. Jun 2019
Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design
BACKGROUND:
Osteoarthritis (OA) leads to joint failure and total joint replacement (TJR, either hip (H) or knee (K)). Worsening of pain and joint space narrowing are believed to be surrogates for joint failure; however, we hypothesize that TJR, as a reflection of joint failure, can be used as an en…
Read the publication
Journal:
Authors:
Bone, Rheumatology, Osteoarthritis
5. Jun 2019
A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model
OBJECTIVES:
Pain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor a…
Read the publication
Journal:
Authors:
- Katri A,
- Dabrowska A,
- Lövfall H,
- Karsdal MA,
- Andreassen KV,
- Thudium CS,
- Henriksen K,
Rheumatology, Osteoarthritis
7. Sep 2018
IL-37 diminishes proteoglycan loiss in human OA cartilage: donor-specific link between IL-37 and MMP-3.
OBJECTIVE:
A hallmark of osteoarthritis (OA) is degradation of articular cartilage proteoglycans. In isolated human OA chondrocytes, the anti-inflammatory cytokine Interleukin-37 (IL-37) lowers the expression of the proteolytic MMP and ADAMTS enzymes, which mediate this degradation. Therefore, we i…
Read the publication
Journal:
Authors:
- Van Geffen EW,
- Van Caam APM,
- Van de Loo FA,
- Van Lent PLEM,
- Koenders MI,
- Thudium CS,
- Bay-Jensen AC,
- Blaney Davidson EN,
- Van der Kraan PM,
Rheumatology, Osteoarthritis
29. Jul 2018
Tofacitinib and TPCA-1 Exert Chondroprotective Effects on Extracellular Matrix Turnover in Bovine Articular Cartilage Ex vivo.
OBJECTIVE:
Currently, there are no disease-modifying osteoarthritis drugs (DMOADs) approved for osteoarthritis. It is hypothesized that a subtype of OA may be driven by inflammation and may benefit from treatment with anti-inflammatory small molecule inhibitors adopted from treatments of rheumatoid…
Read the publication
Journal:
Authors:
- Kjelgaard-Petersen CF,
- Sharma N,
- Kayed A,
- Karsdal MA,
- Mobasheri A,
- Hägglund P,
- Bay-Jensen AC,
- Thudium CS,
Rheumatology, Osteoarthritis
25. Apr 2018
Protein biomarkers associated with pain mechanisms in osteoarthritis
Osteoarthritis (OA) is the most common arthritic disease in the world, leading to debilitating pain and destruction of joint tissues. While pain is the hallmark symptom of osteoarthritis, clear associations between pain and disease processes involved in joint deterioration are lacking. OA pain is mu…
Read the publication
Journal:
Authors:
- Thudium CS,
- Löfvall H,
- Karsdal MA,
- Bay-Jensen AC,
- Bihlet A,
Bone, Extracellular Matrix Research, Osteoarthritis
10. Apr 2018
Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes
BACKGROUND:
Osteoclasts have been strongly implicated in osteoarthritic cartilage degradation, at least indirectly via bone resorption, and have been shown to degrade cartilage in vitro. The osteoclast resorption processes required to degrade subchondral bone and cartilage-the remodeling of which i…
Read the publication
Journal:
Authors:
- Löfvall H,
- Newbould H,
- Karsdal MA,
- Dziegiel MH,
- Richter J,
- Henriksen K,
- Thudium CS,
Rheumatology, Osteoarthritis
16. Oct 2017
Development and use of biochemical markers in osteoarthritis: current update
PURPOSE OF REVIEW:
There is an increasing demand for noninvasive and descriptive biochemical markers (biomarkers) in osteoarthritis; for enabling early drug development (including translational research), evaluating clinical trial at an early stage and for subtyping. Purpose of the review is to rev…
Read the publication
Journal:
Authors:
- Bay-Jensen AC,
- Thudium CS,
- Mobasheri A,
Rheumatology, Osteoarthritis
14. Oct 2017
Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development
Osteoarthritis (OA) is the most common form of joint disease. This presents the OA research community and pharmaceutical companies developing disease-modifying OA drugs (DMOADs) with great opportunities. The different OA subtypes complicate the traditional approaches for developing new treatments. I…
Read the publication
Journal:
Authors:
- Bay-Jensen AC,
- Thudium CS,
- Mobasheri A,
- Gualillo O,
Rheumatology, Osteoarthritis, Obesity
9. Sep 2017
A machine learning approach for the identification of new biomarkers for knee osteoarthritis development in overweight and obese women
OBJECTIVE:
Knee osteoarthritis (OA) is among the higher contributors to global disability. Despite its high prevalence, currently, there is no cure for this disease. Furthermore, the available diagnostic approaches have large precision errors and low sensitivity. Therefore, there is a need for new …
Read the publication
Journal:
Authors:
- Bacardit J,
- Henrotin Y,
- Bierma-Zeinstra SMA,
- Thudium CS,
- Bay-Jensen AC,
- Runhaar J,
- Lazzarini N,
Extracellular Matrix Research, Osteoarthritis
22. Mar 2017
Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine IL-6 are related to synovitis and pain in endstage knee osteoarthritis patients
Little is known about local and systemic biomarkers in relation to synovitis and pain in end-stage osteoarthritis (OA) patients. We investigated the associations between the novel extracellular matrix biomarker, C1M, and local and systemic interleukin 6 (IL-6) with synovitis and pain. Serum C1M, pla…
Read the publication
Journal:
Authors:
- Radojcic MR,
- Thudium CS,
- Henriksen K,
- Tan K,
- Karlsten R,
- Dudley A,
- Chessell I,
- Karsdal MA,
- Bay-Jensen AC,
- Arbit E,
- Guermazi A,
Rheumatology, Osteoarthritis
25. Jan 2016
Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria
OBJECTIVE:
To review and summarize biomarker data published from April 2014 to May 2015 to provide insight to the ongoing work in the field of osteoarthritis (OA). Furthermore, to summarize the BIPED criteria and set it in context of the medical needs of 2015.
METHODS:
PubMed was used as search…
Read the publication
Journal:
Authors:
- Bay-Jensen AC,
- Reker D,
- Kjelgaard-Petersen CF,
- Mobasheri A,
- Karsdal MA,
- Ladel C,
- Henrotin Y,
- Thudium CS,